Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - sugammadex sodium, quantity: 554 mg (equivalent: sugammadex, qty 500 mg) - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - sugammadex arx is indicated for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - sugammadex sodium, quantity: 217.6 mg (equivalent: sugammadex, qty 200 mg) - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - sugammadex arx is indicated for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lurasidone hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; lactose monohydrate; iron oxide yellow; titanium dioxide; hydroxypropyl distarch phosphate; hypromellose; citric acid; povidone; macrogol 6000; mannitol; indigo carmine aluminium lake - msn-lurasidone is indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lurasidone hydrochloride, quantity: 40 mg - tablet, film coated - excipient ingredients: citric acid; magnesium stearate; titanium dioxide; croscarmellose sodium; carnauba wax; povidone; hydroxypropyl distarch phosphate; lactose monohydrate; macrogol 400; hypromellose; mannitol - msn-lurasidone is indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

reach pharmaceuticals pty ltd - cabazitaxel, quantity: 60 mg - injection, diluent for - excipient ingredients: ethanol; water for injections - msn cabazitaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.

Australia - English - Department of Health (Therapeutic Goods Administration)

reach pharmaceuticals pty ltd - fosaprepitant dimeglumine, quantity: 245.3 mg (equivalent: fosaprepitant, qty 150 mg) - injection, powder for - excipient ingredients: lactose; polysorbate 80; hydrochloric acid; sodium hydroxide; disodium edetate - fosaprepitant msn, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy (see section 4.2 dose and method of administration),? moderately emetogenic cancer chemotherapy (see section 4.2 dose and method of administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - purified water; naloxegol oxalate, quantity: 14.2 mg (equivalent: naloxegol, qty 12.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; propyl gallate; iron oxide black; microcrystalline cellulose; titanium dioxide; macrogol 400; iron oxide red; mannitol; magnesium stearate; hypromellose - movantik is indicated for the treatment of opioid-induced constipation (oic) in adult patients who have had an inadequate response to laxative(s).

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - purified water; naloxegol oxalate, quantity: 28.5 mg (equivalent: naloxegol, qty 25 mg) - tablet, film coated - excipient ingredients: iron oxide black; magnesium stearate; croscarmellose sodium; hypromellose; microcrystalline cellulose; titanium dioxide; macrogol 400; mannitol; propyl gallate; iron oxide red - movantik is indicated for the treatment of opioid-induced constipation (oic) in adult patients who have had an inadequate response to laxative(s).